IDEAYA Biosciences, Inc. (IDYA): Total Assets
$1.11B
As of 2025-12-31
$1.31B
As of 2026-06-30
+41.9%
3-year compound annual growth
+30.0%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.11B | -1.3% | 2026-02-17, Balance as of period end |
| 2024-12-31 | $1.12B | +73.1% | 2026-02-17, Balance as of period end |
| 2023-12-31 | $649.32M | +67.4% | 2025-02-18, Balance as of period end |
| 2022-12-31 | $387.97M | +1.7% | 2024-02-20, Balance as of period end |
| 2021-12-31 | $381.35M | +27.9% | 2023-03-07, Balance as of period end |
| 2020-12-31 | $298.27M | +164.0% | 2022-03-18, Balance as of period end |
| 2019-12-31 | $113.00M | +17.0% | 2021-03-23, Balance as of period end |
| 2018-12-31 | $96.54M | n/a | 2020-03-24, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $1.11B | -1.3% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $488.95M | -25.5% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $670.77M | -2.1% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $216.30M | +1.4% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $364.39M | -24.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $376.56M | +70.6% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $338.02M | -45.1% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $1.14B | -1.0% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $480.20M | +22.4% |
Compare IDYA, VNDA, AMRN, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗